21 May 2024: Original Paper
Liver Transplantation from Brain-Dead Donors with Hepatitis B or C in South Korea: A 2014–2020 Korean Organ Transplantation Registry Data Analysis
Hoonsung Park 12CDEF , Hanyoung Lee 3CDF , Seungmin Baik 4DF , Myoung Soo Kim 5ABG , Jaeseok Yang 6ABG , Jong Cheol Jeong 7ABG , Tai Yeon Koo 8ABG , Deok-Gie Kim 9ABG , Jae-Myeong Lee 3ACDFG*DOI: 10.12659/AOT.943588
Ann Transplant 2024; 29:e943588
Table 3 Outcomes of liver transplantation.
| HBV(+) graft recipients (n=24) | HCV(+) graft recipient (n=1) | HBV(−)/HCV(−) graft recipients (n=1010) | p value | |
|---|---|---|---|---|
| 35.1±24.6 | 12 | 32.1±24.6 | HBV(+)−HBV(−)/HCV(−): p=0.58 | |
| HBV(+)−HBV(−)/HCV(−): p=1 | ||||
| Once | 23 (95.8%) | 1 (100%) | 960 (95%) | |
| Twice | 1 (4.2%)a) | 0 | 48 (4.8%) | |
| Thrice | 0 | 0 | 2 (0.2%) | |
| 24.0±18.8 | 48 | 37.1±37.6 | HBV(+)−HBV(−)/HCV(−): p=0.09 | |
| HBV(+)−HBV(−)/HCV(−): p=0.11 | ||||
| Infection | 0 | 0 | 93 (44.8%) | |
| Cardiovascular disease | 1 (33.3%) | 0 | 7 (3.4%) | |
| Cerebrovascular disease | 0 | 0 | 14 (6.8%) | |
| Hepatic failure | 1 (33.3%) | 0 | 49 (23.7%) | |
| Recurred HCC | 0 | 0 | 11 (5.4%) | |
| Accident or trauma | 0 | 0 | 1 (0.5%) | |
| Suicide | 0 | 0 | 1 (0.5%) | |
| Other/unknown | 1 (33.3%) | 0 | 31 (14.9%) | |
| HBV(+)−HBV(−)/HCV(−): p=0.8 | ||||
| Patient death with functioning graft | 3 (75%) | 0 | 136 (66.6%) | |
| Primary non-function | 1 (25%) | 0 | 25 (12.3%) | |
| Hepatic artery complication | 0 | 0 | 6 (2.9%) | |
| Hepatic vein/IVC complication | 0 | 0 | 2 (1%) | |
| Portal vein complication | 0 | 0 | 2 (1%) | |
| Biliary complication | 0 | 0 | 5 (2.5%) | |
| Acute rejection | 0 | 0 | 8 (3.9%) | |
| Chronic rejection | 0 | 0 | 2 (1%) | |
| Drug related toxicity | 0 | 0 | 3 (1.5%) | |
| Recurred liver disease | 0 | 0 | 1 (0.5%) | |
| Recurred HCC | 0 | 0 | 6 (2.9%) | |
| Other/unknown | 0 | 0 | 8 (3.9%) | |
| HBV(+)−HBV(−)/HCV(−): p=0.23 | ||||
| Bleeding from operation site | 1 (25%) | 0 | 101 (19.8%) | |
| Intraperitoneal abscess | 1 (25%) | 0 | 30 (5.9%) | |
| Hepatic artery stenosis/thrombosis | 0 | 0 | 14 (2.8%) | |
| Hepatic artery aneurysm | 0 | 0 | 3 (0.6%) | |
| Portal vein stenosis/thrombosis | 1 (25%) | 0 | 17 (3.3%) | |
| Hepatic vein stenosis/thrombosis | 0 | 0 | 16 (3.1%) | |
| IVC stenosis/thrombosis | 0 | 0 | 13 (2.6%) | |
| Bile leakage | 0 | 0 | 36 (7.1%) | |
| Bile duct stenosis | 1 (25%) | 0 | 106 (20.8%) | |
| Biliary stone | 0 | 0 | 17 (3.3%) | |
| Others | 0 | 0 | 156 (30.7%) | |
| HBV(+)−HBV(−)/HCV(−): p=0.29 | ||||
| Anti-T-lymphocyte-globulin | 0 | 0 | 0 | |
| Basiliximab | 17 | 1 | 816 | |
| N/A | ||||
| Tacrolimus | 18 | 1 | 941 | |
| Cyclosporin | 0 | 0 | 8 | |
| Everolimus | 3 | 0 | 38 | |
| HBV(+)−HBV(−)/HCV(−): p=1 | ||||
| Mycophenolate mofetil | 13 (100%) | 1 | 616 (98.7%) | |
| Mycophenolate sodium | 0 | 0 | 8 (1.3%) | |
| HBV(+)−HBV(−)/HCV(−): p=1 | ||||
| Deflazacort | 0 | 0 | 22 (2.6%) | |
| Prednisolone | 17 (100%) | 1 | 836 (97.4%) | |
| 5 (5/24, 20.8%) | 0 | 9 (9/313, 2.9%) | HBV(+)−HBV(−)/HCV(−): p | |
| 0 (0/1, 0%)b) | 0 | 32 (32/66, 48.5%) | HBV(+)−HBV(−)/HCV(−): p=1 | |
| 1 (1/4, 25%) | 0 (0/1, 0%) | 32 (32/179, 17.9%) | HBV(+)−HBV(−)/HCV(−): p=0.55 | |
| None | 1 (4.2%) | 0 | 531 (52.6%) | HBV(+)−HBV(−)/HCV(−): p |
| Done | 23 (95.8%) | 0 | 479 (47.4%) | HBV(+)−HBV(−)/HCV(−): p |
| HBIG only | 1 (4.3%) | 0 | 184 (38.4%) | |
| Anti-viral only | 4 (17.4%) | 0 | 7 (1.5%) | |
| HBIG + anti-viral | 18 (78.3%) | 1c) | 288 (60.1%) | |
| IVC – inferior vena cava; HCC – hepatocellular carcinoma; HBIG – hepatitis B immunoglobulin. a) b) c) | ||||